9 September 2025
Rybelsus® tablets are being updated to a new formulation with improved bioavailability. This new version is bioequivalent to the original but comes in different strengths and tablet shapes.
Dose Comparison
|
Original Formulation (Oval Tablet) |
New Formulation (Round Tablet) |
|---|---|
|
3 mg (starting dose) |
1.5 mg (starting dose) |
|
7 mg (maintenance dose) |
4 mg (maintenance dose) |
|
14 mg (maintenance dose) |
9 mg (maintenance dose) |
Key Points to Know:
- The new formulation has the same efficacy, safety profile, and method of administration as the original.
- Rybelsus should always be taken as one tablet once daily.
- Both formulations will temporarily co-exist on the market. This may lead to confusion or dosing errors, increasing the risk of adverse effects.
- Patients currently taking Rybelsus should be informed about the change and advised accordingly when the new formulation is prescribed or dispensed.
- New patients starting Rybelsus will begin treatment with the updated formulation.
Further information can be found here.